TerminatedPHASE1, PHASE2NCT01251965

Phase l/II Study of Ruxolitinib for Acute Leukemia

Studying Acute lymphoblastic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
M.D. Anderson Cancer Center
Principal Investigator
Srdan Verstovsek, MD
M.D. Anderson Cancer Center
Intervention
Ruxolitinib(drug)
Enrollment
27 target
Eligibility
14 years · All sexes
Timeline
20102012

Study locations (1)

Collaborators

Incyte Corporation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01251965 on ClinicalTrials.gov

Other trials for Acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute lymphoblastic leukemia

← Back to all trials